GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Steminent Biotherapeutics 7729.TWO · TWD

N/A · Taipei Exchange · 🇹🇼 Taiwan

Compare

201.00

+7.20%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

—

FY2020FY2025

Net income

−TWD 174.0m

FY2020FY2025

Free cash flow

−TWD 140.1m

FY2020FY2025

Shareholders' equity

TWD 601.1m

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Revenue——TWD 941,000TWD 636,000TWD 2.1mTWD 51.5m
Gross profit—−TWD 16.4m−TWD 1.0m−TWD 8.9m−TWD 1.7mTWD 28.5m
Research and developmentTWD 115.3mTWD 110.4mTWD 67.7mTWD 55.4mTWD 48.1mTWD 44.2m
Operating income−TWD 173.7m−TWD 162.3m−TWD 131.5m−TWD 98.2m−TWD 75.6m−TWD 43.0m
Net income−TWD 174.0m−TWD 158.7m−TWD 129.2m−TWD 85.5m−TWD 124.2m−TWD 55.2m
Diluted earnings per share-2.89-2.83-2.32-1.42-2.06-0.92

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assetsTWD 698.5mTWD 436.7mTWD 593.9mTWD 235.7mTWD 279.5mTWD 100.2m
Cash and short-term investments—TWD 217.0mTWD 451.9mTWD 153.4mTWD 230.6mTWD 40.8m
Total liabilitiesTWD 97.3mTWD 82.0mTWD 100.9mTWD 72.1mTWD 35.2mTWD 113.2m
DebtTWD 21.7mTWD 63.8mTWD 75.4mTWD 55.2mTWD 19.2mTWD 26.8m
Shareholders' equityTWD 601.1mTWD 354.7mTWD 493.0mTWD 163.5mTWD 244.3m−TWD 13.0m
Shares outstanding60m56m56m60m60m60m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−TWD 132.3m−TWD 139.4m−TWD 114.8m−TWD 69.2m−TWD 55.1m−TWD 31.5m
Capital spending−TWD 7.8m−TWD 88.4m−TWD 27.7m−TWD 2.5m−TWD 600,000—
Free cash flow−TWD 140.1m−TWD 227.8m−TWD 142.5m−TWD 71.7m−TWD 55.7m−TWD 31.5m

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023
Revenue————TWD 941,000
Gross profit−TWD 15.4m−TWD 8.7m−TWD 7.7m−TWD 7.1m−TWD 4.8m
Operating income−TWD 78.8m−TWD 76.5m−TWD 85.8m−TWD 87.9m−TWD 43.5m
Net income−TWD 80.6m−TWD 75.1m−TWD 83.6m−TWD 87.1m−TWD 42.2m
Diluted earnings per share-1.34-1.34-1.49-1.56-0.76
Cash from operations−TWD 68.0m−TWD 59.0m−TWD 79.0m−TWD 72.0m−TWD 41.0m
Capital spending−TWD 4.0m−TWD 38.0m−TWD 48.0m−TWD 25.0m−TWD 2.0m
Free cash flow−TWD 72.0m−TWD 97.0m−TWD 127.0m−TWD 97.0m−TWD 43.0m
Total assetsTWD 377.3mTWD 436.7mTWD 505.3mTWD 593.9mTWD 472.6m
Cash and short-term investmentsTWD 164.5mTWD 217.0mTWD 318.0mTWD 451.9mTWD 360.4m
DebtTWD 39.6mTWD 27.4mTWD 26.9mTWD 26.3mTWD 10.6m
Shareholders' equityTWD 279.8mTWD 354.7mTWD 422.2mTWD 493.0mTWD 378.3m

Financial ratios

Data as of 16 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin——-110.1%-1404.1%-82.3%55.4%
Operating margin——-13543.8%-13298.1%-5793.3%-98.6%
Net margin——-13733.2%-13439.3%-5855.8%-107.3%
Return on equity-29.0%-44.8%-26.2%-52.3%-50.8%425.2%
Return on assets-24.9%-36.4%-21.8%-36.3%-44.4%-55.1%
Free cash flow yield-1.1%-0.5%-0.8%———
Revenue growth——48.0%-70.0%-95.9%—
Earnings growth9.6%22.8%51.2%-31.2%125.0%—
Current ratio13.58x7.43x12.07x6.68x10.79x2.90x
Debt to equity0.04x0.08x0.05x0.09x0.06x-1.17x
Equity ratio86.1%81.2%83.0%69.4%87.4%-13.0%
Interest coverage-79.85x-81.82x-71.52x-94.18x-92.67x-64.27x
R&D as a share of sales——7197.2%8712.4%2267.3%86.0%
Buybacks as a share of market value-7.5%-0.4%————

Growth per year

Compound annual rate

3 years5 years10 years
Operating income20.9%32.2%—
Net income26.7%25.8%—

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-20.8-8.1

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.